Skip to main content
OpenTrials
Completed

NCT Number: NCT00562315

FACBC PET/CT for Recurrent Prostate Cancer

Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients.

This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called [18]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called [18]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called [18]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done.

Anti-[18F]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention.

This study will look at how the [18]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Emory University Hospital

Atlanta, Georgia, 30322, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

STUDY NOW CLOSED for recruitment

Inclusion criteria

  • Patients must be 18 years of age or older.
  • Patients will have been originally diagnosed with localized (Stage T1c, T2, or T3 ) prostate carcinoma and have undergone what was considered definitive therapy for localized disease.
  • In the case of brachytherapy, cryotherapy, or external beam radiation, treatment will have occurred at least 2 years in the past to eliminate patients with so-called "PSA bump."
  • Patient will have suspicion of recurrent prostate carcinoma as defined by: ASTRO criteria of three consecutive rises of PSA or earlier if clinically appropriate, and/or nadir + 2.0 after radiotherapy, and/or greater than 0.3 after prostatectomy.
  • Ability to lie still for PET scanning
  • Patients must be able to provide written informed consent.

Exclusion criteria

  • Age less than 18.
  • Greater than T3 disease in past
  • Prior prostatectomy or 2 years since brachytherapy, cryotherapy, or external beam radiation therapy.
  • Does not meet above criteria of suspicious PSA elevation
  • Inability to lie still for PET scanning
  • Cannot provide written informed consent.
  • Bone scan findings characteristic for metastatic prostate carcinoma
  • Less than 2 months since any prior prostate biopsy (to decrease false positive uptake from inflammation).

Treatment and study plan

FACBC

Drug

Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan

Other names: Fluciclovine

ProstaScinct

Other

ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.

Other names: In-Capromab Pendetide

Primary outcomes

  1. Number of Participants With True Positive Scans Within the Prostate Bed

    Time frame: Up to 5 years

    Total number of participants with positive FACBC PET-CT and ProstaScint CT scans in diagnosis of prostate cancer in the prostate bed validated by prostate biopsy and follow up.

  2. Number of Participants With False Positive Scans Within the Prostate Bed

    Time frame: Up to 5 years

    Total number of participants with positive FACBC PET-CT and ProstaScint scans in the prostate bed that were confirmed as negative by biopsy and or follow up.

  3. Number of Participants With True Negative Scans Within the Prostate Bed

    Time frame: Up to 5 years

    Total number of participants with negative FACBC PET-CT and ProstaScint CT scans in the prostate bed that were confirmed as negative by biopsy and or follow up.

  4. Number of Participants With False Negative Scans Within the Prostate Bed

    Time frame: Up to 5 years

    Total number of participants with negative FACBC PET-CT and ProstaScint CT scans in the prostate bed that were confirmed as positive by biopsy and or follow up.

  5. Number of Participants With True Positive Scans Outside the Prostate Bed

    Time frame: Up to 5 years

    Total number of participants with positive FACBC PET-CT and ProstaScint CT scans outside the prostate bed (extra-prostate) that were confirmed as positive by biopsy and/or follow up.

  6. Number of Participants With True Negative Scans Outside the Prostate Bed

    Time frame: Up to 5 years

    Total number of participants with negative FACBC PET-CT and ProstaScint CT scans outside the prostate bed (extra-prostate) that were confirmed as negative by biopsy and/or follow up.

  7. Number of Participants With False Positive Scans Outside the Prostate Bed

    Time frame: Up to 5 years

    Total number of participants with positive FACBC PET-CT and ProstaScint CT scans outside the prostate bed (extra-prostate) that were confirmed as negative by biopsy and/or follow up.

  8. Number of Participants With False Negative Scans Outside the Prostate Bed

    Time frame: Up to 5 years

    Total number of participants with negative FACBC PET-CT and ProstaScint CT scans outside the prostate bed (extra-prostate) that were confirmed as positive by biopsy and/or follow up.

  9. Diagnostic Performance of Anti-[18F]FACBC PET-CT Imaging in Detection of Extra-prostatic Recurrence of Prostate Carcinoma

    Time frame: Up to 5 years

    • Sensitivity = How well FACBC PET is able to correctly detect when there is prostate cancer outside the prostate bed. [total number of true positives / total number of study participants confirmed to have prostate cancer outside the prostate bed (True positives + False negatives)]
    • Specificity = How well FACBC PET is able to correctly detect when there is no prostate cancer outside the prostate bed. [ total number of true negatives / total number of study participants confirmed to not have prostate cancer outside the prostate bed (True negatives + False positives)]
    • Accuracy = (True positives + true negatives)/all tests
    • Positive predictive value = probability that subjects with a positive screening test truly have prostate cancer outside the prostate bed
    • Negative predictive value = probability that subjects with a negative screening test truly don't have prostate cancer outside the prostate bed

  10. Diagnostic Performance of Anti-[18F]FACBC PET-CT Imaging in Detection of Recurrent Prostate Carcinoma in the Prostate Bed

    Time frame: Up to 5 years

    • Sensitivity = How well FACBC PET is able to correctly detect when there is prostate cancer in the prostate bed. i.e. total number of true positives / total number of study participants confirmed to have prostate disease in the prostate bed (True positives + False negatives)
    • Specificity = How well FACBC PET is able to correctly detect when there is no prostate cancer in the prostate bed. i.e. total number of true negatives / total number of study participants confirmed to not have prostate disease in the prostate bed (True negatives + False positives)
    • Accuracy = (True positives + true negatives)/all tests
    • Positive predictive value = the probability that subjects with a positive screening test truly have prostate carcinoma in the prostate bed
    • Negative predictive value = the probability that subjects with a negative screening test truly don't have prostate carcinoma in the prostate bed

Secondary outcomes

  1. Diagnostic Performance of ProstaScint Imaging in Detection of Recurrent Prostate Carcinoma in the Prostate Bed

    Time frame: Up to 5 years

    • Sensitivity = How well ProstaScint imaging is able to correctly detect when there is prostate cancer in the prostate bed. i.e. total number of true positives / total number of study participants confirmed to have prostate disease in the prostate bed (True positives + False negatives)
    • Specificity = How well ProstaScint imaging is able to correctly detect when there is no prostate cancer in the prostate bed. i.e. total number of true negatives / total number of study participants confirmed to not have prostate disease in the prostate bed (True negatives + False positives)
    • Accuracy = (True positives + true negatives)/all tests
    • Positive predictive value = the probability that subjects with a positive screening test truly have prostate carcinoma in the prostate bed
    • Negative predictive value = the probability that subjects with a negative screening test truly don't have prostate carcinoma in the prostate bed

  2. Diagnostic Performance of ProstaScint Imaging in Detection of Extra-prostatic Recurrence of Prostate Carcinoma

    Time frame: Up to 5 years

    • Sensitivity = How well ProstaScint is able to correctly detect when there is prostate cancer outside the prostate bed. [total number of true positives / total number of study participants confirmed to have prostate cancer outside the prostate bed (True positives + False negatives)]
    • Specificity = How well ProstaScint is able to correctly detect when there is no prostate cancer outside the prostate bed. [ total number of true negatives / total number of study participants confirmed to not have prostate cancer outside the prostate bed (True negatives + False positives)]
    • Accuracy = (True positives + true negatives)/all tests
    • Positive predictive value = the probability that subjects with a positive screening test truly have prostate cancer outside the prostate bed
    • Negative predictive value is the probability that subjects with a negative screening test truly don't have prostate cancer outside the prostate bed

Sponsors and collaborators

Lead sponsor

David M. Schuster, MD

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

18F-FACBC PET-CT for the Detection and Staging of Recurrent Prostate Carcinoma (CA129356-01).

Important dates

Study start
2007
Primary completion
2015
Study completion
2015
First posted
Nov 22, 2007
Registry last updated
Jun 21, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.